Form 13-F position report

ZENTALIS PHARMACEUTICALS INC

Reported by ALLIANCEBERNSTEIN L P

ZNTL CUSIP 98943L107 Manager CIK 0001109448

Reported 17,100 shares, unchanged from the prior quarter.

Reported value 18.4%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 17,100 Quarter-end amount reported
Reported value $47,367 Fair value at quarter end
Consecutive quarters held 2 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 77918000
2022-03-31 45990000
2022-06-30 38060000
2022-09-30 28849000
2022-12-31 27501130
2023-03-31 22193091
2023-06-30 37277681
2023-09-30 1157823
2023-12-31 874428
2024-03-31 909636
2024-06-30 452918
2024-09-30 403100
2024-12-31 331900
2025-03-31 174165
2025-06-30 0
2026-06-30 40014
2026-09-30 47367

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarterly reported position history for ZENTALIS PHARMACEUTICALS INC held by ALLIANCEBERNSTEIN L P.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 17,100 0 (0.0%) < 0.01% $47,367 2026-11-16
Q2 2026 New 17,100 +17,100 (0.0%) < 0.01% $40,014 2026-08-14
Q2 2025 Reduced 0 -109,538 (-100.0%) 0 $0 2025-08-14
Q1 2025 Unchanged 109,538 0 (0.0%) < 0.01% $174,165 2025-05-15
Q4 2024 Unchanged 109,538 0 (0.0%) < 0.01% $331,900 2025-02-12
Q3 2024 Reduced 109,538 -1,200 (-1.1%) < 0.01% $403,100 2024-11-14
Q2 2024 Added 110,738 +53,020 (91.9%) < 0.01% $452,918 2024-08-14
Q1 2024 Unchanged 57,718 0 (0.0%) < 0.01% $909,636 2024-05-14
Q4 2023 Unchanged 57,718 0 (0.0%) < 0.01% $874,428 2024-02-14
Q3 2023 Reduced 57,718 -1,263,717 (-95.6%) < 0.01% $1,157,823 2023-11-14
Q2 2023 Added 1,321,435 +31,139 (2.4%) 0.02% $37,277,681 2023-08-15
Q1 2023 Reduced 1,290,296 -75,202 (-5.5%) < 0.01% $22,193,091 2023-05-15
Q4 2022 Added 1,365,498 +33,614 (2.5%) 0.01% $27,501,130 2023-02-15
Q3 2022 Reduced 1,331,884 -22,579 (-1.7%) 0.01% $28,849,000 2022-11-15
Q2 2022 Added 1,354,463 +357,704 (35.9%) 0.02% $38,060,000 2022-08-15
Q1 2022 Added 996,759 +69,822 (7.5%) 0.02% $45,990,000 2022-05-13
Q4 2021 Reduced 926,937 -59,016 (-6.0%) 0.03% $77,918,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

140 managers reported ZENTALIS PHARMACEUTICALS INC for Q3 2026.

Managers reporting ZENTALIS PHARMACEUTICALS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Squadron Capital Management LLC Added 6,827,905 +3,127,905 4.75% $18,913,297 3 qtrs
CITADEL ADVISORS LLC Added 4,489,717 +2,191,314 < 0.01% $12,436,516 26 qtrs
5AM Venture Management LLC Unchanged 3,947,913 0 3.68% $10,935,719 14 qtrs
BlackRock Inc Added 3,912,620 +159,095 < 0.01% $10,837,956 9 qtrs
ADAR1 Capital Management LLC Added 3,762,532 +3,109,782 0.44% $10,422,214 6 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 3,523,514 +687,845 < 0.01% $9,760,134 3 qtrs
ACADIAN ASSET MANAGEMENT LLC Added 3,056,124 +374,224 < 0.01% $8,455,000 9 qtrs
TWO SIGMA INVESTMENTS LP Reduced 2,801,386 -223,550 < 0.01% $7,759,839 14 qtrs
Patient Square Capital LP New 2,007,485 +2,007,485 0.89% $5,560,733 1 qtr
Seven Fleet Capital Management LP Added 1,504,231 +1,186,631 0.81% $4,166,720 3 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
17,100
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.